newsfilter
← Latest News
PR Newswire·

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

DisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration CAMBRIDGE, Mass., March 16, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company